CalciMedica (CALC) Interest & Investment Income (2019 - 2022)
CalciMedica's (CALC) quarterly Interest & Investment Income came in at $309000.0 in Q4 2022, up 1088.46% YoY from $26000.0 in Q4 2021, and up 80.7% on a QoQ basis from $171000.0 in Q3 2022.
CalciMedica (CALC) Interest & Investment Income (2019 - 2022) Analysis & Trends
CalciMedica (CALC) has 4 years of Interest & Investment Income data on file, last reported at $309000.0 in Q4 2022.
- Quarterly Interest & Investment Income rose 1088.46% year-over-year to $309000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $575000.0 (up 356.35% YoY) and the FY2022 annual result came in at $575000.0, up 356.35% from the prior year.
- Interest & Investment Income improved to $309000.0 in Q4 2022, from $171000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $309000.0 in Q4 2022 to a low of $3000.0 in Q3 2020.
- A 4-year average of $84714.3 and a median of $37000.0 in 2021 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2020 — Interest & Investment Income tumbled 98.12% — and 2022, when it jumped 1088.46%.
- Tracing CALC's Interest & Investment Income over 4 years: stood at $182000.0 in 2019, then tumbled by 87.36% to $23000.0 in 2020, then grew by 13.04% to $26000.0 in 2021, then jumped by 1088.46% to $309000.0 in 2022.
- The last three Interest & Investment Income figures came in at $309000.0 (Q4 2022), $171000.0 (Q3 2022), and $60000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 309,000.00 |
| Sep 30, 2022 | 171,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | 28,000.00 |
| Jun 30, 2021 | 33,000.00 |
| Mar 31, 2021 | 39,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 108,000.00 |
| Dec 31, 2019 | 182,000.00 |
| Sep 30, 2019 | 160,000.00 |